Skip to content
In conversation with... Kanwal Raghav episode artwork

Aug 28, 2024 13 min

In conversation with... Kanwal Raghav

from Listen to The Lancet Oncology Hosted by The Lancet

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

In conversation with... Kanwal Raghav

0:00 13:22

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 13 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on August 28, 2024.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.